These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30803105)

  • 21. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.
    Gordon SC; Lamerato LE; Rupp LB; Holmberg SD; Moorman AC; Spradling PR; Teshale E; Xu F; Boscarino JA; Vijayadeva V; Schmidt MA; Oja-Tebbe N; Lu M
    Am J Gastroenterol; 2015 Aug; 110(8):1169-77; quiz 1178. PubMed ID: 26215529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
    Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of hepatitis C virus and IL28B genotypes on liver stiffness.
    Lundbo LF; Clausen LN; Weis N; Schønning K; Rosenørn L; Benfield T; Christensen PB
    PLoS One; 2014; 9(12):e115882. PubMed ID: 25545640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
    Bonnard P; Elsharkawy A; Zalata K; Delarocque-Astagneau E; Biard L; Le Fouler L; Hassan AB; Abdel-Hamid M; El-Daly M; Gamal ME; El Kassas M; Bedossa P; Carrat F; Fontanet A; Esmat G
    J Viral Hepat; 2015 Mar; 22(3):245-53. PubMed ID: 25073725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Previously unrecognized advanced liver disease unveiled by transient elastography in patients with Haemophilia and chronic hepatitis C.
    Moessner BK; Andersen ES; Weis N; Laursen AL; Ingerslev J; Lethagen S; Pedersen C; Christensen PB
    Haemophilia; 2011 Nov; 17(6):938-43. PubMed ID: 21435119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C.
    Verveer C; Zondervan PE; ten Kate FJ; Hansen BE; Janssen HL; de Knegt RJ
    Liver Int; 2012 Apr; 32(4):622-8. PubMed ID: 22098684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey.
    Tan YW; Tao Y; Liu LG; Ye Y; Zhou XB; Chen L; He C
    World J Gastroenterol; 2018 Mar; 24(11):1250-1258. PubMed ID: 29568205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening.
    Millbourn C; Psaros Einberg A; Lindh G; Hökeberg I; Fischler B; Lindahl K
    Scand J Gastroenterol; 2018; 53(7):870-875. PubMed ID: 29909701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HCV genotypes and age distribution in patients of Vienna and surrounding areas.
    Haushofer AC; Kopty C; Hauer R; Brunner H; Halbmayer WM
    J Clin Virol; 2001 Jan; 20(1-2):41-7. PubMed ID: 11163582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic hepatitis C in childhood: an 18-year experience.
    Iorio R; Giannattasio A; Sepe A; Terracciano LM; Vecchione R; Vegnente A
    Clin Infect Dis; 2005 Nov; 41(10):1431-7. PubMed ID: 16231253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
    Viola L; Marciano S; Colombato L; Coelho H; Cheinquer H; Bugarin G; Tatsch F; Carvalho-Filho RJ; Roblero JP; Varon A; Holguin J; Torres-Ibarra MR; Pérez-Ríos AM
    Ann Hepatol; 2020; 19(2):161-165. PubMed ID: 31718995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management.
    Gupta RK; Sakhuja P; Majumdar K; Ali S; Srivastava S; Sachdeva S; Sharma BC; Puri AS
    Indian J Pathol Microbiol; 2018; 61(3):345-349. PubMed ID: 30004052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    Chen Yi Mei SLG; Thompson AJ; Christensen B; Cunningham G; McDonald L; Bell S; Iser D; Nguyen T; Desmond PV
    PLoS One; 2017; 12(10):e0185609. PubMed ID: 29065124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.